Targeted radiation zaps advanced prostate cancer in major trial

NCT ID NCT04689828

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new targeted radiation drug (177Lu-PSMA-617) works better than switching to a different standard hormone therapy for men with advanced prostate cancer that has spread and stopped responding to prior hormone treatments. The drug seeks out and delivers radiation directly to prostate cancer cells. The main goal was to see if the new treatment could delay cancer growth or help patients live longer compared to the standard approach.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Med Ctr

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Duke Univ Medical Center

Durham, North Carolina, 27710, United States
Medical College Of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Ctr

New York, New York, 10065, United States
Mount Sinai Hosp Med School

New York, New York, 10029, United States
NYU Laura and Isaac Perlmutter Cancer Center

New York, New York, 10016, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68154, United States
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Linz, 4020, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Roeselare, West-Vlaanderen, 8800, Belgium
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Ghent, 9000, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Vancouver, British Columbia, V5Z 4E6, Canada
Novartis Investigative Site

Montreal, Quebec, H2W 1T8, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Olomouc, 779 00, Czechia
Novartis Investigative Site

Angers, 49055, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Clermont-Ferrand, 63011, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Paris, 75970, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

München, 80377, Germany
Novartis Investigative Site

Nijmegen, Gelderland, 6500HB, Netherlands
Novartis Investigative Site

Maastricht, Limburg, 6229 HX, Netherlands
Novartis Investigative Site

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site

Gliwice, Silesian Voivodeship, 44-101, Poland
Novartis Investigative Site

Bratislava, 83310, Slovakia
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site

El Palmar, Murcia, 30120, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Valencia, Valencia, 46009, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Gothenburg, 413 45, Sweden
Novartis Investigative Site

Lund, 221 85, Sweden
Novartis Investigative Site

Stockholm, 17176, Sweden
Novartis Investigative Site

Baden, 5404, Switzerland
Novartis Investigative Site

Lausanne, 1011, Switzerland
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Guildford, Surrey, GU2 7XX, United Kingdom
Novartis Investigative Site

Sutton, Surrey, SM2 5PT, United Kingdom
Novartis Investigative Site

Coventry, CV2 2DX, United Kingdom
Novartis Investigative Site

London, EC1A 7BE, United Kingdom
Novartis Investigative Site

London, NW1 2BU, United Kingdom
Novartis Investigative Site

London, NW3 2QG, United Kingdom
Novartis Investigative Site

Middlesbrough, TS4 3BW, United Kingdom
Onco Hemato Asso of SW Virginia

Roanoke, Virginia, 24014, United States
Rocky Mountain Cancer Centers

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43221, United States
Tulane Uni Health Sciences Center

New Orleans, Louisiana, 70112, United States
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
University of Florida

Gainesville, Florida, 32610, United States
Urology Cancer Center PC

Omaha, Nebraska, 68130, United States
Utah Cancer Specialists

Salt Lake City, Utah, 84106, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States
WA Uni School Of Med

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

PROSTATIC NEOPLASMS